All News IO Biotech, Inc.

Equities

IOBT

US4497781090

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
1.54 ^USD	+3.36%		+5.48%	-18.09%

26/04	IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	CI
15/04	IO Biotech Announces Marjan Shamsaei as Senior Vice President	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors	27/04	CI
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	25/04	AQ
IO Biotech : Corporate Deck April 2024	17/04	PU
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness	15/04	AQ
IO Biotech Announces Marjan Shamsaei as Senior Vice President	15/04	CI
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103	09/04	AQ
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	09/04	CI
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer	05/04	AQ
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer	05/04	CI
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting	07/03	AQ
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	07/03	CI
IO Biotech : Corporate Deck March 2024	06/03	PU
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results	06/03	AQ
IO Biotech to Present at 44th Annual Cowen Health Care Conference	27/02	AQ
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment	22/12	MT
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	21/12	AQ
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	21/12	CI
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News IO Biotech, Inc.

Equities

IOBT

US4497781090

All News

Filters